Company Focus
Chugai
Latest Chugai News
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Chugai
Biotechnology
Shares of Swiss antibody drug conjugates (ADCs) develop ADC Therapeutics were down more than 11% at $2.55 as it reported financial results for 2nd-qtr 2024 and provided operational updates. 6 August 2024
Pharmaceutical
Germany’s Bayer has reported group revenue of 11.1 billion euros ($12.2 billion) in the second quarter of 2024, ahead of the 10.9 billion euros average of analysts’ estimates and up by 1% on the same period a year ago. 6 August 2024
Pharmaceutical
Shanghai-based Antengene (SEHK: 6996) has announced that the Malaysian medicines regulator has approved Xpovio (selinexor) for the treatment of multiple myeloma. 6 August 2024
Biotechnology
Actinium Pharmaceuticals’ shares closed down 60% yesterday and fell a further 10% to $2.23 in after-hours trading, when the company announced a regulatory setback for its Iead candidate. 6 August 2024
Biotechnology
California’s BioMarin Pharmaceutical (Nasdaq: BMRN) has announced a strategic pivot for its Roctavian (valoctocogene roxaparvovec-rvox) business, focusing on the USA, Germany, and Italy. 6 August 2024
Biotechnology
In Singapore, a division of Kyowa Kirin (TSE:4151), has announced plans to sell the firm’s Chinese business while reducing focus on small molecules, as part of a regional overhaul. 6 August 2024
Biotechnology
Agenus has revealed via a Securities and Exchange Commission (SEC) filing that US pharma major Bristol Myers Squibb (NYSE: BMS) was pulling out of a licensing deal. 5 August 2024
Biotechnology
German biotech BioNTech today reported financial results for the three ended June 30, 2024, which failed to impress.. 5 August 2024
Biotechnology
Shares of Genmab dipped 2.6% to 1,867 kroner in early trading, as the Danish drugmaker revealed that the return of rights to acasunlimab by German biotech BioNTech 5 August 2024
Biotechnology
Clinical trial results featured heavily in the news last week, first with Dutch biotech NewAmsterdam releasing data on its hypercholesterolemia candidate obicetrapib. US drug developer MacroGenics announced receipt of a $100 million milestone from Incyte relating to progress in its deal on Zynyz and updated on the development of prostate cancer drug vobra duo. Germany’s BioNTech announced top-line Phase II results of its mRNA cancer immunotherapy BNT111. Also, US pharma major Eli Lilly released new data on its GLP-1 drug tirzepatide – already marketed for diabetes and obesity under the trade names Mounjaro and Zepbound, respectively - in heart failure. 4 August 2024
Latest In Brief for Chugai
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
13 November 2024
30 October 2024
28 October 2024
26 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze